OFATUMUMAB (Kesimpta ®)
For treating relapsing multiple sclerosis
In line with NICE TA699
Implementation date 19th August 2021
Date of classification
Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).